Healthcare Industry News: Elekta
News Release - November 18, 2015
Amethyst Radiotherapy Orders Elekta Cancer Treatment Solutions for European ExpansionHigh-end linear accelerators to be delivered to clinics in France, Poland and Romania
STOCKHOLM, November 18, 2015 -- (Healthcare Sales & Marketing Network) -- Elekta (EKTA-B.ST) will deliver advanced radiotherapy equipment and services to Amethyst Radiotherapy, a private cancer treatment network serving Western and Central Europe. The value of the order, approximately EUR 28 million, was booked in the second quarter of Elekta's fiscal year.
With a focus on radiation oncology, Amethyst Radiotherapy's medical teams treated over 4,000 patients in 2014 at clinics in France, Poland and Romania. It continues to be one of Europe's fastest growing medical networks and expects to have 20 clinics and a total of 42 linear accelerators by the end of 2020.
Barbara Werchowiecka-Rusinek, Amethyst Radiotherapy's CEO, says: "In order to treat patients well and safely, we needed a proven and experienced technological partner. Therefore we chose Elekta to equip our radiotherapy centers in Bucharest and Cluj (Romania) and Krakow (Poland), and now even as we upgrade our centers in France."
She adds: "In May this year, we performed our first radiosurgery, removing a tumor in a patient's brain and saving her life. We are the only ones to offer such advanced therapeutic treatment in the regions where we are located, which is a great benefit for patients. Our success is due in part to our cooperation with Elekta and the high precision and reliability of its accelerators, as well as the professionalism of the team who supervises their operation."
Francois Pointurier, Senior Vice President, Region Europe & AFLAME at Elekta, says: "According to the Lancet Oncology Commission there are substantial health and economic benefits in using radiotherapy and huge investments need to be made to meet the world's needs. We are pleased that Amethyst sees the potential of radiotherapy and that they have chosen Elekta as their supplier."
Rashid Oozeer, Chief Medical Physicist at Amethyst Radiotherapy, says: "Amethyst Radiotherapy is helping to satisfy the demand for radiation therapy treatment in Europe as it opens new clinics and furnishes existing sites with the most advanced radiotherapy equipment and software. Elekta delivers the technologies our clinics rely on, such as intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic radiotherapy, image-guided radiotherapy (IGRT) and high definition brachytherapy."
As the company expands in Western and Central Europe, it will equip its treatment centers with state-of-the-art devices, including Versa HD™, the most modern linear accelerator on the market. In addition to Versa HD, the agreement also includes Elekta Infinity™ linear accelerators, brachytherapy devices, MOSAIQ® oncology information system and services.
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on November 18, 2015.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: http://www.Elekta.com .
1. Expanding Global Access to Radiotherapy DOI: http://dx.doi.org/10.1016/S1470-2045(15)00222-3
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.